Novo Nordisk A/S $NVO Holdings Boosted by Everett Harris & Co. CA

Everett Harris & Co. CA raised its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 0.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,407,366 shares of the company’s stock after purchasing an additional 13,586 shares during the period. Novo Nordisk A/S accounts for 3.9% of Everett Harris & Co. CA’s holdings, making the stock its 6th biggest position. Everett Harris & Co. CA’s holdings in Novo Nordisk A/S were worth $326,007,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the stock. Godfrey Financial Associates Inc. purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $25,000. WealthCollab LLC lifted its stake in shares of Novo Nordisk A/S by 93.5% in the fourth quarter. WealthCollab LLC now owns 538 shares of the company’s stock worth $27,000 after buying an additional 260 shares in the last quarter. American National Bank & Trust purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $28,000. Maseco LLP purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $29,000. Finally, Jackson Grant Investment Advisers Inc. purchased a new position in shares of Novo Nordisk A/S in the fourth quarter worth about $29,000. 11.54% of the stock is owned by hedge funds and other institutional investors.

Novo Nordisk A/S Price Performance

Shares of NVO stock opened at $41.05 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 0.79 and a quick ratio of 0.56. The firm’s 50-day moving average is $41.71 and its two-hundred day moving average is $46.12. Novo Nordisk A/S has a 12 month low of $35.12 and a 12 month high of $81.44. The company has a market capitalization of $183.31 billion, a PE ratio of 9.64, a price-to-earnings-growth ratio of 3.83 and a beta of 0.78.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Tuesday, March 31st. The company reported $1.03 EPS for the quarter. Novo Nordisk A/S had a net margin of 37.23% and a return on equity of 63.31%. The company had revenue of $10.85 billion for the quarter. Analysts predict that Novo Nordisk A/S will post 3.46 earnings per share for the current year.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Novo Nordisk said its oral Wegovy pill has surpassed 3 million U.S. prescriptions in just over five months, suggesting very strong adoption and broadening use among patients who had not previously taken a GLP-1 drug.
• Positive Sentiment: Real-world data reportedly show Ozempic 2 mg performing competitively against Eli Lilly’s Mounjaro on glucose control and weight-loss outcomes, which supports Novo’s diabetes franchise. Article: Novo Nordisk Real-World Data Supports Ozempic Against LLY’s Mounjaro
• Positive Sentiment: Novo also highlighted investigational zenagamtide data showing 14.6% weight loss in adults with type 2 diabetes, reinforcing optimism around its pipeline. Article: Novo Nordisk’s Investigational Zenagamtide Shows 14.6% Weight Loss In Adults With Type-2 Diabetes
• Positive Sentiment: The company continues its share repurchase program, which can help support earnings per share and signals management confidence. Article: Novo Nordisk A/S – share repurchase programme
• Neutral Sentiment: Several articles framed Novo and Lilly as locked in a major race for the GLP-1 pill market ahead of Medicare coverage decisions, underscoring the long-term opportunity but also the competitive risk. Article: Novo and Lilly are competing to win the GLP-1 pill market as they prepare for Medicare coverage
• Negative Sentiment: Eli Lilly’s oral GLP-1 pill reportedly outperformed rival therapies in late-stage diabetes trials, highlighting the competitive threat facing Novo Nordisk. Article: LLY Stock Climbs As Oral GLP-1 Pill Beats Novo Nordisk, AstraZeneca’s Therapies In Diabetes Trials
• Negative Sentiment: Investors also appeared disappointed that Novo’s ADA conference updates did not materially improve the company’s near-term competitive outlook, contributing to the stock’s weakness. Article: Novo Nordisk shares retreat after ADA conference updates fail to excite investors (NVO)

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on NVO. Morgan Stanley raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $40.00 price target on the stock in a research note on Tuesday, March 3rd. Zacks Research raised shares of Novo Nordisk A/S from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 10th. Kepler Capital Markets downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research note on Tuesday, February 24th. Nordea Equity Research downgraded shares of Novo Nordisk A/S to a “hold” rating in a research note on Tuesday, February 24th. Finally, The Goldman Sachs Group reissued a “neutral” rating and issued a $41.00 price target (down from $63.00) on shares of Novo Nordisk A/S in a research note on Monday, March 2nd. Four investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Hold” and a consensus price target of $65.56.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.